期刊文献+

脑膜瘤PR、ER、AR、p53、Ki-67、MYC、VEGF检测的临床意义

Expression of progesterone receptor, estrogen receptor, androgen receptor, Ki-67, p53, MYC, and vascular endothelial growth factor in meningioma tissue
下载PDF
导出
摘要 目的 观察脑膜瘤组织中孕激素受体(PR)、雌激素受体(ER)、雄激素受体(AR)、p53、Ki-67、MYC、血管内皮细胞生长因子(VEGF)的表达,探讨它们与脑膜瘤恶性变及复发的关系.方法 收集64例脑膜瘤标本,应用组织芯片技术检测PR 、ER、AR、p53、Ki-67、MYC、VEGF在脑膜瘤细胞中的表达情况并进行分析.结果 PR、VEGE、p53、Ki-67、MYC在不同级别脑膜瘤组织中表达的差异有统计学意义(P<0.05或0.01).PR 、p53、Ki-67、MYC在复发与未复发脑膜瘤中表达的差异有统计学意义(P<0.05或0.01).结论 PR阴性并且p53、Ki-67、MYC高表达的脑膜瘤易复发及恶变. Objective To determine the expressions of progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR),P53,Ki-67, MYC and vascular endothelial growth factor (VEGF) in human meningioma tissue and to investigate its significance. Methods The expressions of PR,ER,p53,AR,Ki-67,MYC and VEGF were detected on microarrays by Immunohistochemistry in 64 tissue specimens of meningioma. Results The expressions of PR,VEGE,p53,Ki-67 and MYC proteins were correlated with the malignancy degree of meningioma (P〈0.05 or P〈0.01). There were significant differences in expression rates of PR,AR,p53,Ki-67and MYC between recurrent and nonrecurrent meningioma (P〈0.01 or P〈0.05). Conclusion Meningioma with high expression of p53, Ki-67, MYC and negative expression of PR shows high degree of malignancy and is more likely to relapse.
作者 顾云彪 周涛
出处 《浙江医学》 CAS 2012年第12期993-995,共3页 Zhejiang Medical Journal
基金 临海市科技计划项目(062KY07)
关键词 脑膜瘤 孕酮受体 P53 KI-67 MYC Meningioma Progesterone receptor p53 Ki-67 MYC
  • 相关文献

参考文献12

  • 1万经海,李长元,江澄川脑膜瘤[M]上海:复旦大学出版社、上海医科大学出版社,2002:50-53.
  • 2王学民,李军,杜波,陈鑫,李德全,刘文康,刘镭.组织芯片的制备技术[J].诊断病理学杂志,2002,9(6):370-371. 被引量:14
  • 3温进坤,韩梅医学的生物学理论与研究技术[M].北京:学技术出版社,2002:54-57.
  • 4Pomeroy S L,Tamayo P,Gaascnbeek M,et aI.Prediction of central nervous system embryonal tumour outcome based off gene ex- pression [J]. Nature, 2002,415:436-442.
  • 5Wrobel G, Roerig P,Kokocinski F,et al. Microarray based gene expression profiling of benign,atypical and anaplastic menin- giomas identifies novel genes associated with meniugiotua pro- gression [J]. Int Cancer, 2005,114:249-256.
  • 6Taddei G L, Caldarella A, Raspollini M R,et al. Estrogen and progesterone recepetors in meningiomas: immunohistochemical (Mib-1 ,p53) and clinico-morphological corretations [J]. Patholog- ica,2002,94(1):10.
  • 7de la Fuente M T, Casanova B, Canteru E, et al. Involvement of p53 in alpha4belal integrin-mediated resistance Of B-CLL cells to fludarabine [J].Biochem Biophys Res Commun, 2003, 311: 708-712.
  • 8McArthur C P,Wang Y, Hertuh D,et al. Amplification of extracel- lular matrix and Oncogenes in tat-transfected human salivary gland cell lines with expression of laminin,fibrouectin,collagens I, III,LV,c-myc and p53 [J]. Arch Oral Biol, 2001,46:545-555.
  • 9Leu S J,Lam S C, & Lan L F. Pro-angiogenic activities of cYR6 (CCNI)mediated thmugh integfins alphavbeta3 and alpha6 beta in human umbilical vein endothalial cells [J] .Bjol Chem, 2002,277: 46248-46255.
  • 10Mezquita P, Parghi S S,Brandvold K A,et al. Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation[J]. Oncogene, 2005,24:889-901.

二级参考文献6

  • 1Kononen J, Bubendorf L, Kallioniemi A, et al.Tissue microarrays for high -throughput molecular profiling of tumor of spectimens. Nat Med, 1998,4:844
  • 2Rimmal I, Camp RL, Charette LA, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J,2.001,7:24
  • 3Kallioniem OP, Wagner U, Kononen J, et al.Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet,2001,10:657
  • 4Bubendof L, Nocito A, Moch H, et al.Tissue microarray(TMA)technology:miniaturized pathology archives for high-throughput in situ studies. J Pathol, 2001,195:72
  • 5Moch H, Kononen J, et al.Tissue microarrays: what will they bring to molecular and anatomic pathology 2001,8:4
  • 6黄晓峰.组织的取材和固定方法[A].见王伯纭 主编.病理学技术[C].北京:人民卫生出版社,2000.61-174.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部